4,800 Shares in STERIS plc $STE Purchased by Andra AP fonden

Andra AP fonden bought a new stake in shares of STERIS plc (NYSE:STE) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 4,800 shares of the medical equipment provider’s stock, valued at approximately $1,153,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in STE. Geneos Wealth Management Inc. increased its position in shares of STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 104 shares during the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of STERIS in the 1st quarter valued at approximately $37,000. Costello Asset Management INC acquired a new position in shares of STERIS in the 1st quarter worth approximately $45,000. Atticus Wealth Management LLC purchased a new position in shares of STERIS during the second quarter worth $68,000. Finally, SVB Wealth LLC acquired a new stake in shares of STERIS in the first quarter valued at $69,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Insider Buying and Selling at STERIS

In other STERIS news, VP Renato Tamaro sold 3,204 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $249.24, for a total value of $798,564.96. Following the completion of the transaction, the vice president owned 7,221 shares in the company, valued at approximately $1,799,762.04. This represents a 30.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Cynthia L. Feldmann sold 3,495 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $241.56, for a total transaction of $844,252.20. Following the completion of the transaction, the director directly owned 705 shares of the company’s stock, valued at approximately $170,299.80. This trade represents a 83.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 18,868 shares of company stock worth $4,585,389. 1.07% of the stock is currently owned by company insiders.

STERIS Trading Up 1.5%

NYSE STE opened at $263.88 on Friday. STERIS plc has a 12 month low of $200.98 and a 12 month high of $265.56. The company has a market capitalization of $25.99 billion, a price-to-earnings ratio of 40.41 and a beta of 1.02. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.22 and a quick ratio of 1.53. The firm’s fifty day moving average price is $243.98 and its 200 day moving average price is $239.00.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.09. STERIS had a net margin of 11.61% and a return on equity of 14.17%. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same period last year, the firm posted $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, sell-side analysts expect that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th will be given a dividend of $0.63 per share. The ex-dividend date is Tuesday, November 18th. This represents a $2.52 annualized dividend and a yield of 1.0%. STERIS’s payout ratio is presently 36.21%.

Analyst Upgrades and Downgrades

STE has been the topic of several research reports. Morgan Stanley increased their target price on STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a research note on Friday, August 8th. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. KeyCorp raised their price objective on shares of STERIS from $277.00 to $288.00 and gave the company an “overweight” rating in a research note on Tuesday, July 22nd. Finally, Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $273.50.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.